Buy Geftinat : Gefitinib 250 Mg Tablets 30’S Online

Description

Description: Geftinat is a medication used in the treatment of non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene. It contains gefitinib as its active ingredient, which belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Gefitinib works by targeting and inhibiting the activity of the EGFR tyrosine kinase, a protein involved in the growth and spread of cancer cells.

Benefits:

1. Treatment of Non-Small Cell Lung Cancer (NSCLC): Geftinat is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific mutations in the EGFR gene. It is used as first-line therapy in patients whose tumors harbor EGFR mutations, such as exon 19 deletions or exon 21 (L858R) substitutions.
2. EGFR Tyrosine Kinase Inhibition: Gefitinib selectively targets and inhibits the activity of the EGFR tyrosine kinase, a key component of the EGFR signaling pathway that is often dysregulated in NSCLC. By inhibiting EGFR activity, gefitinib blocks downstream signaling pathways involved in cancer cell proliferation, survival, and angiogenesis, leading to tumor shrinkage and inhibition of disease progression.
3. Oral Administration: Geftinat is administered orally as once-daily tablets, making it convenient for patients to take at home. The tablets should be taken on an empty stomach, at least one hour before or two hours after meals, to optimize absorption and efficacy.
4. Improved Quality of Life: Treatment with Geftinat has been shown to improve progression-free survival and overall survival in patients with EGFR mutation-positive NSCLC, leading to improved quality of life and symptom control. It can help delay disease progression, reduce tumor burden, and alleviate cancer-related symptoms such as cough, dyspnea, and fatigue.

Precautions and Side Effects:

While generally well-tolerated, Geftinat may cause side effects in some individuals, including diarrhea, rash, acne, dry skin, nausea, vomiting, and decreased appetite. Less common but more serious side effects may include interstitial lung disease (ILD), liver toxicity, and ocular disorders. Patients receiving gefitinib should be monitored closely for signs of toxicity, and treatment may need to be interrupted or discontinued if severe adverse reactions occur.

Conclusion:

Geftinat, manufactured by Natco Pharma Ltd., is a medication used in the treatment of non-small cell lung cancer (NSCLC) with specific mutations in the EGFR gene. With its targeted inhibition of EGFR tyrosine kinase activity, Geftinat offers effective treatment options for patients with EGFR mutation-positive NSCLC, leading to improved outcomes and quality of life. However, it is essential to use this medication under the guidance of a qualified healthcare professional and to monitor patients closely for potential side effects and toxicity.